SEATTLE-November 16, 2022 -(BUSINESS WIRE)–Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, today announced the closing of a $26 million Series A1 financing round. This brings total funding raised in 2022 to $86M for the…Read More
Thank you Tim for all your contributions. You helped us navigate a period of rapid growth through an incredibly complex space and we’re grateful for that. We’ve made significant progress under your leadership. You jumped into the deep end and helped us be a better company. I genuinely wish you every success in whatever you choose to do next.